Modern drugs put many patients into remission, yet clinicians cannot reliably predict who will relapse or when inflammation will return.

The new findings suggest cell death in IBD is not just a by-product of inflammation. It may act as one of the earliest triggers of the disease itself. Professor James Murphy, a WEHI deputy director and lab head who co-led the work, said the team deliberately looked past the most obvious damage.

"We've gone to the other end of the spectrum and looked at gut tissue that doesn't have clear signs of active disease," Murphy said. "What we're finding is this molecular defect happening very early in disease progression — one of the first dominoes to fall."

How was the study built?

The research relied entirely on human tissue, a deliberate choice away from the mouse models that dominate IBD research.

Professor Edwin Hawkins, head of the Colonial Foundation Diagnostics Center, said that decision sets the work apart.

"While cell death has been implicated in IBD for a long time, how it arises in humans has remained unclear, probably because most studies rely on mouse models which often do not accurately mimic the human condition," Hawkins said. "Our study is based on human tissue and patient biopsies."

The team then tracked patients for more than two years, linking molecular readings from biopsies to clinical outcomes over time.

Could this lead to a new test or therapy?

Not immediately. The authors stress that translating a basic molecular finding into a clinical tool takes years of additional work. Dr. Jiyi Pang, a study co-author, said the signals offer a starting point for predictive tests and more targeted treatment.

"The causes of IBD are largely unknown and quite variable," Pang said. "We now have the hallmarks of what underlies disease at the molecular level. The question is which of those are therapeutically actionable."

Dr. Aysha Al-Ani was more cautious, noting the work opens research avenues rather than solving the problem.

"It opens new avenues for different prognostic tools, using more sophisticated and refined methods than are currently used clinically," Al-Ani said.

What are the limits of the work?

• The cohort included 80 people, large enough to detect a signal but small by clinical-trial standards.
• Researchers followed patients for more than two years; longer follow-up could clarify how stable the signal remains.
• Detecting the defect requires molecular profiling of biopsies, not a routine blood test.
• The design shows association between cell-death signaling and relapse, not proof that abnormal cell death causes IBD.

Who else worked on the study?

The research pulled in teams from WEHI, the University of Melbourne, the Royal Melbourne Hospital, the Royal Children's Hospital, the Monash Institute of Pharmaceutical Sciences, the Hudson Institute of Medical Research, and Monash University.

Funding came from the Kenneth Rainin Foundation, the National Health and Medical Research Council of Australia, the Australian Research Council, the Stafford Fox Medical Research Foundation, the Colonial Foundation, Crohn's and Colitis Australia, and the Victorian State Government.

The journal paper carries the DOI 10.1126/science.aeh7112.